Preview Mode Links will not work in preview mode

Apr 8, 2019

Acute Leukemias Update — Part 2: Our interview with Dr Ravandi highlights the following topics as well as cases from his practice:

  • Impact of genetic mutations and cytogenetic alterations on prognosis and therapy selection for patients with AML (00:00)
  • Initial workup for patients with newly diagnosed AML (03:38)
  • Biologic rationale for, activity of and approval of venetoclax in combination with hypomethylating agents for patients with AML who are 75 or older or have comorbidities (05:48)
  • Integration of venetoclax with hypomethylating agents into the clinical algorithm for AML (10:50)
  • Approach to therapy for older patients with AML and FLT3 mutations(12:43)
  • Management of toxicities associated with venetoclax combined with a hypomethylating agent (15:08)
  • RATIFY: Results of a Phase III trial evaluating midostaurin with 7 + 3 induction and high-dose cytarabine consolidation and as maintenance therapy for patients with newly diagnosed AML and FLT3 mutations (18:25)
  • Efficacy of sorafenib, quizartinib or gilteritinib for patients with AML and FLT3 mutations (21:57)
  • Side effects and spectrum of activity of gilteritinib, quizartinib and midostaurin (25:09)
  • Case: A 70-year-old man with AML and NPM1 and FLT3 mutations receives azacitidine in combination with venetoclax and sorafenib as third-line therapy (29:06)
  • Case: A 44-year-old woman with AML and an IDH2 mutation receives enasidenib (31:32)
  • Perspective on the potential use of enasidenib or ivosidenib in the first-line setting (34:52)
  • Mechanism of action and efficacy of CPX-351 in patients with therapy-related AML or AML with myelodysplasia-related changes (37:45)
  • Clinical experience with CPX-351 (40:23)
  • Role of gemtuzumab ozogamicin in the treatment of CD33-positive AML (42:57)
  • Activity of the recently approved hedgehog inhibitor glasdegib in combination with low-dose cytarabine for newly diagnosed AML in patients aged 75 or older or those with comorbidities (46:27)
  • Case: A 75-year-old woman with AML and significant comorbidities is enrolled on a clinical trial of decitabine with venetoclax (47:58)
  • Case: A 76-year-old woman with ALL experiences a complete remission with blinatumomab as second-line therapy (51:46)
  • Mechanism of action and efficacy of blinatumomab for ALL (55:52)
  • Activity and tolerability of CAR T-cell therapy for ALL (57:50)
  • Cytokine release syndrome and neurologic toxicities associated with CAR T-cell therapy and blinatumomab (59:52)
  • Perspective on the role of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive ALL (1:02:09)
  • Efficacy of gemtuzumab ozogamicin in patients with high-risk APL (1:04:46)


Select publications